|Patients’ conditions||Number of patients||Comparison||Survival||p Value|
|*CR = colorectal; CHT = chemotherapy; combination CHT = 5-FU, leucovorin, and cisplatin; ELF = 5-FU, leucovorin, and etoposide; FLv = 5-FU and leucovorin.|
|†Patients could receive SC.|
|‡Significant only after correction for imbalances in pretreatment characteristics.|
|Advanced CR and stomach cancer refractory to CHT||107||Octreotide† v SC||20 v 11 weeks||<0.0001|
|Metastatic CR cancer that progressed within 6 months of treatment with fluorouracil||279||Irinotecan plus SC v SC||9.2 v 6.5 months||0.0001|
|Previously untreated, inoperable, locally recurrent or metastatic CR cancer||36||Combination CHT plus SC v SC||11 v 5 months||0.006|
|Advanced, surgically incurable stomach cancer||61||ELF or FLv plus SC v SC||8 v 5 months||0.003‡|
Review: chemotherapy plus supportive care improves survival and quality of life in advanced or metastatic gastrointestinal cancer more than supportive care alone
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>
EBN Journal Chat
The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries
from Evidence Based Nursing (EBN).
How to participate >>
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.